Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents

Cancer Biology and Therapy

Volumn 3, Issue 3, 2004, Pages 326-337

  Dang, Long H ^a,f   Bettegowda, Chetan ^a   Agrawal, Nishant ^a,b   Cheong, Ian ^a   Huso, David ^b   Frost, Philip ^c   Loganzo, Frank ^c   Greenberger, Lee ^c   Barkoczy, Jozsef ^d   Pettit, George R ^d   Smith III, Amos B ^e   Gurulingappa, Hallur ^a   Khan, Saeed ^a   Parmigiani, Giovanni ^a   Kinzler, Kenneth W ^a   Zhou, Shibin ^a   Vogelstein, Bert ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c WYETH RESEARCH   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anaerobic bacteria; Angiogenesis; Bacteriolytic therapy; Cancer therapy; Hypoxia; Microtubule inhibitors; Tumor vasculature

Indexed keywords

14 NORMETHYLDISCODERMOLIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AURISTATIN PE; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; D 24851; DISCODERMOLIDE; DOCETAXEL; DOLASTATIN 10; EPOTHILONE B; MAC 321; NAVELBINE; NOSCAPINE; PACLITAXEL; PROBIOTIC AGENT; TALTOBULIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; BACTERIAL TOXIN; CLOSTRIDIUM NOVYI ALPHA TOXIN; CLOSTRIDIUM NOVYI ALPHA-TOXIN; DRUG DERIVATIVE; HTI-286; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CELL KILLING; CLOSTRIDIUM; CLOSTRIDIUM NOVYI NT; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ERADICATION THERAPY; FEMALE; GERMINATION; INHIBITION KINETICS; MICROTUBULE; MOUSE; NECROSIS; NONHUMAN; NUDE MOUSE; PERFUSION; SYNTHESIS; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; VASCULAR TUMOR; ANIMAL; BACTERIAL SPORE; C57BL MOUSE; EXPERIMENTAL NEOPLASM; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOGENICITY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIAL TOXINS; CLOSTRIDIUM; MICE; MICE, INBRED C57BL; MICE, NUDE; MICROTUBULES; NECROSIS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; REGIONAL BLOOD FLOW; SPORES; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE;

EID: 6344253429     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.3.704     Document Type: Article

References (42)

1. Houghton JA. Developing novel and highly effective new therapeutic strategies for treatment of colorectal cancer: Where do we go from here? Curr Opin Investig Drugs 2001; 2:674-6.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-8.
3. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21:505-15.
4. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1:453-8.
5. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-16.
6. Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Natl Acad Sci USA 2001; 98:14748-50.
7. Heppner F, Mose JR. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir (Wien) 1978; 42:123-5.
8. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17:37-41.
9. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002; 9:291-6.
10. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 27:27.
11. Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002; 62:1935-8.
12. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48:353-74.
13. Pettit GR. The dolastatins. Fortschr Chem Org Naturst 1997; 70:1-79.
14. Smith IA, Kaufman MD, Beachamp TJ, LaMarche MJ, Arimoto H. Gram-Scale Synthesis of (+)-Discodermolide. Org Lett 2000; 2:1983.
15. Altmann KH. Epothilone B and its analogs - a new family of anticancer agents. Mini Rev Med Chem 2003; 3:149-58.
16. Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003; 63:1838-45.
17. Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003; 2:873-84.
18. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 1989; 25:503-10.
19. 2 arrest after DNA damage. Science 1998; 282:1497-501.
20. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999; 96:9236-41.
21. Diggle PJ LK-Y, Zeger SL. Analysis of Longitudinal Data: Oxford University Press, 1994.
22. Petak I, Tillman DM, Houghton JA. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000; 6:4432-41.
23. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000; 11:419-32.
24. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003; 4:141-8.
25. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002; 83:21-38.
26. Bernsen HJ, Rijken PF, Hagemeier NE, van der Kogel AJ. A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res 1999; 57:244-57.
27. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001; 7:928-34.
28. Tsutsui K, Minami J, Matsushita O, Katayama S, Taniguchi Y, Nakamura S, et al. Phylogenetic analysis of phospholipase C genes from Clostridium perfringens types A to E and Clostridium novyi. J Bacteriol 1995; 177:7164-70.
29. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide. Br J Cancer 2000; 83:811-6.
30. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol 2001; 2:82-7.
31. Hamel E, Covell DG. Antimitotic peptides and depsipeptides. Curr Med Chem Anti-Canc Agents 2002; 2:19-53.
32. ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996; 35:243-50.
33. Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000; 2:555-60.
34. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-33.
35. Martello LA, LaMarche MJ, He L, Beauchamp TJ, Smith AB, Horwitz SB. The relationship between Taxol and (+)-discodermolide: Synthetic analogs and modeling studies. Chem Biol 2001; 8:843-55.
36. Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Durkin KP, Boyd MR, et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 1995; 10:529-44.
37. Woyke T, Pettit GR, Winkelmann G, Pettit RK. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE. Antimicrob Agents Chemother 2001; 45:3580-4.
38. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001; 61:392-9.
39. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer Suppl 1996; 27:S86-8.
40. Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, Adams AW, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002; 62:4109-14.
41. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 1991; 27:482-7.
42. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 2001; 84:290-5.